Cargando…

Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) has been renamed metabolic dysfunction-associated fatty liver disease (MAFLD), a condition for which there is now no authorized treatment. The search for new medications to treat MAFLD made from natural substances is gaining traction. The function of anti-oxi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jing, Feng, Quansheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929346/ https://www.ncbi.nlm.nih.gov/pubmed/35308224 http://dx.doi.org/10.3389/fphar.2022.854674

Ejemplares similares

A Review of the Pharmacological Action of Astragalus Polysaccharide
por: Zheng, Yijun, et al.
Publicado: (2020)

Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics
por: Feng, Yanbo, et al.
Publicado: (2021)

Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women
por: Zhao, ChenLu, et al.
Publicado: (2023)

Protective Effects and Mechanisms of Yinchen Linggui Zhugan Decoction in HFD-Induced Nonalcoholic Fatty Liver Disease Rats Based on Network Pharmacology and Experimental Verification
por: Jiang, Hui, et al.
Publicado: (2022)

Explore the Mechanism of Astragalus mongholicus Bunge against Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Experimental Verification
por: Fu, Lili, et al.
Publicado: (2022)

Astragalus and its formulas as a therapeutic option for fibrotic diseases: Pharmacology and mechanisms
por: Zhu, Yi, et al.
Publicado: (2022)

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease
por: Song, Chong, et al.
Publicado: (2023)

Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
por: Cui, Huantian, et al.
Publicado: (2020)

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021)

UHPLC Q-Exactive MS-Based Serum Metabolomics to Explore the Effect Mechanisms of Immunological Activity of Astragalus Polysaccharides With Different Molecular Weights
por: Li, Ke, et al.
Publicado: (2020)

Study on the Mechanism of Astragalus Polysaccharide in Treating Pulmonary Fibrosis Based on “Drug-Target-Pathway” Network
por: Bing, Pingping, et al.
Publicado: (2022)

Editorial: Nonalcoholic fatty liver disease therapy: Exploring molecular mechanisms of well-defined composition from natural plants
por: Zhang, Wenji, et al.
Publicado: (2022)

Network Pharmacology-Based Analysis of Pogostemon cablin (Blanco) Benth Beneficial Effects to Alleviate Nonalcoholic Fatty Liver Disease in Mice
por: Cui, Yizhe, et al.
Publicado: (2021)

WTAP mediates the anti-inflammatory effect of Astragalus mongholicus polysaccharide on THP-1 macrophages
por: Long, Haijiao, et al.
Publicado: (2022)

Gut microbiota mediated hypoglycemic effect of Astragalus membranaceus polysaccharides in db/db mice
por: Song, Qianbo, et al.
Publicado: (2022)

Astragalus Polysaccharides/Chitosan Microspheres for Nasal Delivery: Preparation, Optimization, Characterization, and Pharmacodynamics
por: Wang, Saisai, et al.
Publicado: (2020)

Integrating Network Pharmacology and Experimental Validation to Investigate the Effects and Mechanism of Astragalus Flavonoids Against Hepatic Fibrosis
por: An, Lin, et al.
Publicado: (2021)

Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease
por: Li, Hu, et al.
Publicado: (2022)

Seabuckthorn polysaccharide combined with astragalus polysaccharide ameliorate alcoholic fatty liver by regulating intestinal flora
por: Liu, Jiayue, et al.
Publicado: (2022)

The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review
por: Kong, Fanming, et al.
Publicado: (2021)

Integrated Metagenomic and Metabolomic Analyses of the Effect of Astragalus Polysaccharides on Alleviating High-Fat Diet–Induced Metabolic Disorders
por: Hong, Ying, et al.
Publicado: (2020)

Mitochondrial Protection and Anti-aging Activity of Astragalus Polysaccharides and Their Potential Mechanism
por: Li, Xing-Tai, et al.
Publicado: (2012)

The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method
por: Liu, Cun, et al.
Publicado: (2019)

The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice
por: Sun, Qin-Juan, et al.
Publicado: (2021)

Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
por: Liu, Yingying, et al.
Publicado: (2022)

Astragalus Polysaccharides Alleviate Type 2 Diabetic Rats by Reversing the Expressions of Sweet Taste Receptors and Genes Related to Glycolipid Metabolism in Liver
por: Luo, Meng-Juan, et al.
Publicado: (2022)

Astragalus Polysaccharide Reduces Blood Pressure, Renal Damage, and Dysfunction Through the TGF-β1-ILK Pathway
por: Zheng, Wei, et al.
Publicado: (2021)

Investigation of the mechanism of the anti-cancer effects of Astragalus propinquus Schischkin and Pinellia pedatisecta Schott (A&P) on melanoma via network pharmacology and experimental verification
por: Wang, Fang, et al.
Publicado: (2022)

Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology
por: Liu, Yingying, et al.
Publicado: (2023)

Editorial: Nonalcoholic fatty liver disease: From pathogenesis to phytomedicine based on omics technology
por: Ji, Guang, et al.
Publicado: (2022)

Molecular mechanism and research progress on pharmacology of ferulic acid in liver diseases
por: Shi, Yingying, et al.
Publicado: (2023)

Astragalus Polysaccharides Ameliorate Diet-Induced Gallstone Formation by Modulating Synthesis of Bile Acids and the Gut Microbiota
por: Zhuang, Qian, et al.
Publicado: (2021)

Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease
por: Jeznach-Steinhagen, Anna, et al.
Publicado: (2019)

Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease
por: Wang, Xue-Kai, et al.
Publicado: (2021)

Protective Effects of Tiaoganquzhi Decoction in Treating inflammatory Injury of Nonalcoholic Fatty liver Disease by Promoting CGI-58 and Inhibiting Expression of NLRP3 Inflammasome
por: Zhang, Huicun, et al.
Publicado: (2022)

Wendan decoction in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2022)

Molecular Weight and Monosaccharide Composition of Astragalus Polysaccharides
por: Xu, Du-Juan, et al.
Publicado: (2008)

Radix Astragalus Polysaccharide Accelerates Angiogenesis by Activating AKT/eNOS to Promote Nerve Regeneration and Functional Recovery
por: Zhang, Geyi, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease
por: Yang, Keungmo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jlsjsim2v1iscqev2kg2qpi8p2